What 6 Analyst Ratings Have To Say About NeoGenomics
Portfolio Pulse from Benzinga Insights
NeoGenomics (NASDAQ:NEO) received mixed analyst ratings with 4 bullish and 2 somewhat bullish out of 6 recent reviews. Analysts adjusted their price targets, leading to an average target of $20.67, up from $20.60. The company operates cancer-focused genetic testing labs and has shown a revenue growth of 12.15% as of December 31, 2023, but struggles with a net margin of -9.21% and an ROA of -0.85%. Its debt-to-equity ratio is below industry average at 0.65.
March 18, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
NeoGenomics received mixed analyst ratings, with an updated average price target of $20.67. The company shows revenue growth but faces profitability challenges.
The mixed analyst ratings with both upgrades and downgrades reflect uncertainty about NeoGenomics' future performance. The slight increase in the average price target suggests a cautiously optimistic outlook. However, the company's financial challenges, such as a negative net margin and ROA, may dampen investor enthusiasm in the short term. The debt-to-equity ratio below industry average is a positive sign, indicating less reliance on debt financing.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100